The significance of the CD6/ALCAM pathway as a disease biomarker and possible target for therapy is highlighted by these findings, which point to urinary ALCAM as a potential biomarker for predicting renal pathogenic activity in LN. The gene discussed is CD6; the disease is lobular neoplasia.